Olson, Peter

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 1,967

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell

Immune cells in cancerTGF-β signaling in diseases

Cited by 1,515

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1,304

Acquired Resistance to KRAS G12C Inhibition in Cancer

Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 1,247

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 769

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer

Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development

Pancreatic and Hepatic Oncology ResearchTGF-β signaling in diseases

Cited by 674

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 653

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 553

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 308

PPARγ activation in adipocytes is sufficient for systemic insulin sensitization

Sugii, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S.-H., Castro, G. L., Yin, Y.-Q., Nelson, M. C., et al. (2009) · Proceedings of the National Academy of Sciences

Peroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 255

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 168

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 142

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 140

Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity

Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 120

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Tang, K. H., Li, S., Khodadadi-Jamayran, A., Jen, J., Han, H., Guidry, K., Chen, T., Hao, Y., Fedele, C., Zebala, J. A., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersProtein Tyrosine Phosphatases

Cited by 105

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 91

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

Riely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 77

Breaching the Cancer Fortress

Olson, P., & Hanahan, D. (2009) · Science

Pancreatic and Hepatic Oncology ResearchAngiogenesis and VEGF in Cancer

Cited by 62

Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

Briere, D. M., Calinisan, A., Aranda, R., Sudhakar, N., Hargis, L., Gatto, S., Fernandez-Banet, J., Pavlicek, A., Engstrom, L. D., Hallin, J., et al. (2019) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 13

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Awad, M., Liu, S., Arbour, K., Zhu, V., Johnson, M., Heist, R., Patil, T., Riely, G., Jacobson, J., Dilly, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 12

Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer

Marx, M. A., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Briere, D. M., Burgess, L. E., Burkhard, M. R., Chiang, H., Chicarelli, M. J., et al. (2020) · Molecular Cancer Research

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 11

Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models

Hallin, J., Calinisan, A., Hargis, L., Aranda, R., Engstrom, L. D., Briere, D. M., Marx, M. A., Olson, P., & Christensen, J. G. (2020) · Cancer Research

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 2